Table 2.
Proportion of respondents who recommend routine screening for anal cancer prevention, by risk sub-group (N = 140).
| Risk Sub-group | n (%) |
|---|---|
| People Living with HIV (PLWH), by gender and sexual partner | |
| HIV-positive Men who have sex with men (MSM)a | 139 (99) |
| HIV-positive Womena | 138 (99) |
| HIV positive Men who have sex with women (MSW) | 128 (91) |
| Non-HIV Immunocompromised | 131 (94) |
| MSM and Transgender Women | |
| HIV-negative MSMa | 122 (87) |
| Transgender women (HIV status not specified)a | 121 (86) |
| Lower Genital Tract Disease (LGTD) | |
| Women with external genital wartsa | 106 (76) |
| Cervicovaginal HSIL | 133 (95) |
| Cervicovaginal Cancer | 137 (98) |
| Vulvar HSIL | 137 (98) |
| Vulvar Cancera | 139 (99) |
Mean respondents who answered “yes”: 130, 95% CI (123, 137).
a
Statistically significant.